HONG KONG – With a booming global market for attention deficit hyperactivity disorder (ADHD) drugs, Durect Corp. is on track to deliver a potentially new, profitable product. The company has achieved positive results in its phase III clinical study of the Oradur-methylphenidate extended-release (ER) capsule administered once a day.